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Abstract 
Background/Aims: Mitochondria-targeted antioxidants such as mitoquinone (MitoQ) 
have demonstrated protective effects against oxidative damage in several diseases. The 
increase in reactive oxygen species (ROS) production during glucose metabolism in β 
cells can be exacerbated under hyperglycaemic conditions such as type 2 diabetes 
(T2D), becoming a key contributor to β cell function impairment. In the present work, 
we aimed to evaluate the effect of MitoQ on oxidative stress, endoplasmic reticulum 
(ER) stress and nuclear factor kappa B (NFκB) signalling in a pancreatic β cell line 
under normoglycaemic (NG, 11.1 mM glucose) and hyperglycaemic (HG, 25 mM 
glucose) conditions. 
Methods: We employed the pancreatic β cell line  INS-1E incubated with or without 
MitoQ (0.5µM) under NG or HG conditions and assessed: O2 consumption with a 
Clark-type electrode; mitochondrial function, oxidative stress parameters and calcium 
levels by fluorescence microscopy; ER stress markers and NFκB-p65 protein levels by 
western blotting. 
Results: Our results showed that MitoQ prevented the enhanced ROS production and O2 
consumption and decreased GSH levels found under HG. MitoQ was also able to reduce 
protein levels of the ER stress markers (GRP78 and P-eif2α) and the proinflammatory 
nuclear transcription factor NFκB-p65, both of which increased under HG. 
Conclusion: Our findings suggest that MitoQ treatment modulates mitochondrial 
function and thereby ameliorates endoplasmic reticulum stress and NFκB activation and 
thus has potential benefits as a treatment for insulin resistance-related diseases such as 
T2D. 
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Non standard abbreviations: ΔΨm, mitochondrial membrane potential; CMFDA, 5-
chloromethylfluorescein diacetate; DCFH-DA, 2’,7’-dichlorodihydrofluorescein 
diacetate; ER, endoplasmic reticulum; FCS, fetal calf serum; Fluo-4 AM, 
(acetyloxy)me-thyl ester; GRP78, glucose-regulated protein 78 chaperone; GSH, 
gluthatione; HG, hyperglycaemia; INS-1E, pancreatic β cells isolated from insulinoma; 
MitoQ, mitoquinone; NFκB, nuclear factor kappa B; NG, normoglycaemia; P-eif2α, 
phosphorylated eukaryotic translation initiation factor 2 alpha; ROS, reactive oxygen 
species; TMRM, tetramethylrhodamine methylester; T2D, type 2 diabetes; TPP, 















During the onset of type 2 diabetes (T2D), glucose homeostasis is altered due to 
an impairment of the compensatory response of β cells [1]. In addition to the destruction 
of pancreatic β cells [2,3], T2D is also associated with oxidative stress and 
mitochondrial dysfunction [4,5,6], with mitochondria representing the main source of 
reactive oxygen species (ROS) in mammalian cells. Therefore, the increase in ROS 
levels that takes place in pancreatic β cells under hyperlipidaemia and hyperglycaemia, 
is one of the key events leading to the impairment of β cell function in T2D [7], 
although the exact underlying mechanisms are yet to be elucidated. 
Under normal conditions, pancreatic β cells metabolize glucose via glycolysis 
and the tricarboxylic acid cycle in order to generate ATP. During this process, ROS are 
released and counteracted by the cell antioxidant defences. Moreover, β cells modulate 
blood glucose concentration by releasing insulin, which occurs when the enhanced 
metabolism of glucose in β cells increases the ATP/ADP ratio and leads to a rapid 
influx of Ca2+, which in turn triggers the release of insulin. Hyperglycaemic conditions 
(HG) such as those found in T2D patients lead to increased ROS production [8,9]. This 
situation can be exacerbated under hyperlipidaemia, during which oxidation of free fatty 
acids-derived acetyl CoA by the TCA cycle and β-oxidation is enhanced, leading again 
to increased ROS production [10]. As pancreatic β cells are highly susceptible to 
oxidative damage [11], antioxidant therapies that improve or avoid oxidative stress may 
help ameliorate damage. 
 Oxidative stress has also been related to endoplasmic reticulum (ER) stress 
under insulin resistance conditions [12]. In fact, ER stress plays an important role in β 
cell impairment under hyperlipidaemic and hyperglycaemic conditions [13,14], and 
constitutes a key mediator of β cell apoptosis [15]. Furthermore, it has been reported 
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that ER stress signalling might be triggered by oxidized LDL through the induction of 
P-eif2α, ATF6 and IRE1α in vascular cells [16]. In addition, oxidative stress can 
activate NFκB, leading to changes in proinflammatory gene expression, eventually 
inducing cardiovascular impairment [17]. 
 Therefore, therapies that decrease mitochondrial impairment, oxidative stress 
and, consequently, ER stress may be of use in the treatment of T2D and its deleterious 
effects [4]. For this reason, mitochondria-targeted antioxidants are emerging as potential 
protective therapies against oxidative damage in cardiovascular diseases, T2D and other 
important diseases [18,19]. The most widely used mitochondria-targeted antioxidant is 
mitoquinone (MitoQ), an ubiquinone derivate that specifically targets mitochondria by 
covalent attachment to a lipophilic triphenylphosphonium (TPP) cation [20,21]. Due to 
the considerable mitochondrial membrane potential (ΔΨm), this cation is accumulated 
within mitochondria inside cells.  
Therefore, the aim of the current study was to evaluate the effect of the 
mitochondria-targeted antioxidant MitoQ on oxidative stress, ER stress and NFκB in the 
pancreatic β cell line INS-1E, as a widely used beta-cell surrogate, under 
normoglycaemic (NG) and HG conditions. 
 
Materials and methods 
Cell culture and treatments 
The insulinoma cell line INS-1E pancreatic β cell was cultured in a humidified chamber 
with 5% CO2 in RPMI-1640 medium (Biowest, Nuaillé, France) at 11.1 mM glucose 
supplemented with 5% (vol./vol.), heat-inactivated foetal calf serum (FCS), 10 mM 
HEPES, 2mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 1 mM 
sodium pyruvate and 50 μM β-mercaptoethanol, as previously described [22]. All 
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experiments were performed on cells from passages 40-50. After 4 days of pre-culture 
in T75 flask, cells were maintained a further 2 days at 11.1 mM glucose (NG) or were 
exposed to a high glucose concentration (25 mM, HG) [23]. Cells were then transferred 
to T25 flasks or 48-well plates and, upon 85% confluency, were treated for 3 hours with 
0.5 µM MitoQ or decyl-TPP, in order to evaluate the non-specific effects of mitoQ. 
Decyl-TPP is similar in hydrophobicity to MitoQ but without the ubiquinol antioxidant 
moiety [24]. Treatments did not affect viability and morphology of these cells. 
 
Measurement of O2 consumption 
INS-1E β cells were detached by trypsinization, counted with a Scepter 2.0 cell 
counter (Millipore Iberica, Madrid, Spain), resuspended (5×106 cells/mL) in Hanks’ 
balanced salt solution (Sigma Aldrich, Missouri, US) and placed in a gas-tight chamber. 
Mitochondrial O2
 consumption was then measured with a Clark-type O2 electrode (Rank 
Brothers, Bottisham, U.K.) [25]. An inhibitor of the electron transport chain, sodium 
cyanide (10-3 mol/L), was used to confirm that O2 consumption was mainly 
mitochondrial (95-99%). 
Membrane potential (ΔΨm), ROS production, glutathione (GSH) and calcium levels 
measurement 
Fluorescence probes tetramethylrhodamine methylester (TMRM; 5×10-6 mol/l), 
MitoSOX (5×10-6 mol/l), 2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA; 5×10-
6 mol/l), 5-chloromethylfluorescein diacetate (CMFDA; 1×10-6 mol/l), and 
(acetyloxy)methyl ester (Fluo-4 AM; 1×10-6 mol/l) were employed to estimate ΔΨm, 
mitochondrial ROS, total ROS, GSH content and calcium levels, respectively. For these 
measurements, cells were seeded in 48-well plates and incubated for 30 min with the 
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respective fluorescent probe. Fluorescence was then measured by fluorometry using a 
fluorescence microscope (IX81; Olympus) coupled to the static cytometry software 
“ScanR” (Olympus). Nuclei were visualized with Hoechst 33342. Measures of 
fluorescence are expressed in arbitrary units. Experiments were performed in triplicate 
and 16 images per well were recorded and analysed. All fluorochromes were purchased 
from Thermo Fisher Scientific, Waltham, US. 
Western blotting (WB) 
Total protein extracts from INS-1E β cells were obtained following the 
previously described treatments by lysing on ice for 15 min with an extraction buffer 
(400 mM NaCl, 20 mM HEPES pH 7.5, 20% Glycerol, 0.1 mM EDTA, 10 μM 
Na2MoO4 and 0.5%, and Nonidet P-40), containing protease inhibitor mixture (10 mM 
NaF, 1 mM Na3VO4, 10 mM PNP, and 10 mM β-glycerolphosphate) and dithiothreitol 
1mM, and performing centrifugation at 4°C for 15 min. Concentration of the isolated 
supernatant containing protein extract was determined using the BCA protein assay kit 
(Thermo Fisher Scientific, IL, US). Twenty-five micrograms of protein were resolved 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then 
transferred to nitrocellulose membranes. After blocking, membranes were incubated 
overnight at 4°C with the following primary antibodies: anti-GRP78 rabbit polyclonal 
antibody (Abcam, Cambridge, MA), anti-P-eif2α-pS52 rabbit polyclonal antibody (Life 
Technologies, California, US), anti-NFκB-p65 rabbit polyclonal antibody (Abcam, 
Cambridge, MA) and anti-actin rabbit polyclonal antibody (Sigma Aldrich, Missouri, 
US). Blots were incubated with the secondary antibody HRP goat anti-rabbit (Millipore 
Iberica, Madrid, Spain) and developed for 2 min with ECL plus reagent (GE Healthcare, 
LC, UK) or Supersignal West Femto (Thermo Fisher Scientific, IL, US). The protein 
signal was detected by chemiluminescence and visualized in a Fusion FX5 acquisition 
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system (Vilbert Lourmat, Marne La Valle´e, France). Images were analysed and 
quantified by densitometry using Bio1D software (Vilbert Lourmat, Marne La Valle´e, 
France) and protein bands were normalized to the expression of actin in the same 
sample. 
Statistical analysis 
Data analysis was performed with SPSS 17.0. Bar graphs show mean ± SEM. 
Data were compared with a one-way analysis of variance (ANOVA) followed by 




An O2 electrode was used to monitor the rate of O2 consumption in INS-1E β 
cells with and without the mitochondria targeted antioxidant MitoQ. The O2 
consumption by the cells was mainly mitochondrial, since addition of sodium cyanide 
resulted in almost complete (95-99%) inhibition of O2 consumption (not shown). Rates 
of O2 consumption in β cells treated and not treated with the mitochondrial targeted 
antioxidant MitoQ remained constant under NG. Interestingly, although HG enhanced 
O2 consumption rates (p<0.05), MitoQ-treated β cells showed a downward trend under 
these conditions (Figure 1A, B). No changes were observed with respect in ΔΨm, 
measured as TMRM fluorescence, in any of the conditions studied (Figure 1C). 
INS-1E β cells exhibited higher levels of MitoSOX oxidation under HG than 
under NG conditions, which is consistent with an increase in mitochondrial ROS 
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production; however, MitoQ decreased MitoSOX oxidation specifically in the cells 
cultured under HG (Figure 1D, p<0.01). 
None of these oxidative stress parameters were affected by treatment with the 
control compound decyl-TPP, which has the same mitochondrial targeting moiety as 
MitoQ but lacks the antioxidant effect. 
Oxidative stress parameters 
Total ROS fluorescence, evaluated by DCFH-DA fluorescence, was 
significantly higher in untreated cells under HG when compared with NG (p<0.05). 
Interestingly, MitoQ treatment decreased total ROS (p<0.05) to values similar to those 
observed under NG conditions, thus revealing a decrease in oxidative stress under HG. 
MitoQ did not alter total ROS in INS-1E β cells under NG (Figure 2A). 
On the other hand, CMFDA fluorescence, which is proportional to the content of 
the free thiol form of GSH in INS-1E β cells, decreased under HG (p<0.05) and was 
restored in the presence of MitoQ (p<0.05), suggesting a protective role. MitoQ did not 
alter the levels of GSH in NG conditions (Figure 2B).  
These results highlight that HG conditions induce oxidative stress in INS-1E β 
cells and that MitoQ prevents it by reducing levels of ROS and preserving antioxidant 
content. None of the oxidative stress parameters were affected by treatment with the 
control compound decyl-TPP. 
ER stress 
As oxidative stress is closely related to ER stress, we investigated whether UPR 
activation occurred in INS-1E β-cells by assessing protein levels of the ER stress 
markers GRP78 and P-eif2α. 
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INS-1E β cells cultured under HG displayed enhanced protein levels of the 
glucose-regulated protein 78 (GRP78) chaperone (Figure 3A) and phosphorylated 
eukaryotic translation initiation factor 2 alpha (P-eif2α, Figure 3B) with respect to 
control cells (p<0.01), which pointed to activation of the UPR in response to HG. These 
effects were reversed in HG conditions by the addition of MitoQ (p<0.01, Figure 3A 
and 3B). MitoQ did not modify protein levels in NG conditions. 
Fluo4-AM fluorescence, employed to measure calcium content, showed a 
similar pattern as that of ER stress proteins. Whereas calcium levels remained constant 
in INS-1E β cells with or without MitoQ under NG conditions, there was an increase in 
intracellular calcium levels in the HG condition that was reverted in the presence of 
MitoQ, suggesting a preventive effect (Figure 3C). Decyl-TPP treatment did not affect 
any of these parameters. 
Levels of NFκβ-p65 
INS-1E β cells showed an increase in NFκB-p65 levels (Figure 4, p<0.01) under 
HG conditions, but MitoQ treatment returned NFκB-p65 protein levels to those 
observed under NG conditions (Figure 4, p<0.01), thus suggesting an anti-inflammatory 
effect. MitoQ did not modify NFκB-p65 levels under NG conditions. Decyl-TPP 
treatment did not affect NFκB-p65 protein expression. 
Discussion 
In the present study we demonstrate that HG induces an increase of 
mitochondrial oxygen consumption, mitochondrial ROS production, ER stress markers 
GRP78 and P-eif2α, calcium levels and NFκB-p65 protein expression, while, on the 
contrary, HG decreases GSH levels in pancreatic β cells. All of these effects were 
restored by treatment with the antioxidant MitoQ. 
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INS-1E is a cell line that displays stable glucose responsiveness and faithfully 
mimics the function of normal pancreatic islets. In addition INS-1E are responsive to 
known potentiators of glucose signalling, which makes them of valuable for studying 
the mechanisms involved in the regulation of insulin secretion. It is important to 
highlight their suitability for testing potential therapeutic agents for diabetes treatment, 
such as mitochondrial targeted antioxidants [26]. 
HG is closely related to oxidative stress and mitochondrial dysfunction [27,28]. 
In this sense, we have previously demonstrated that leukocytes from T2D patients 
presented oxidative stress, mitochondrial dysfunction and ER stress [27]. Furthermore, 
different studies have shown beneficial effects of mitochondrial antioxidant enzymes by 
protecting against oxidative stress under HG [29]. For these reasons, we considered 
whether mitochondria-targeted antioxidants could exert beneficial effects under HG, as 
we have previously demonstrated in leukocytes from T2D patients [30].  In fact, MitoQ 
has been shown to be an effective therapeutic strategy for diabetic nephropathy in the 
Ins2+/-AkitaJ mouse model [18], and promotes the survival and function of pancreatic β 
cells when subjected to glucotoxicity and glucolipotoxicity by improving insulin 
secretion [31]. In addition to the above, we selected MitoQ for the present study due to 
its biocompatibility and safety at levels that have shown efficacy. Previous studies have 
shown that TPP+ compounds, such as MitoQ, when used at typical culture 
concentrations, can affect mitochondrial function depending on the linker group but not 
on antioxidant properties [32] and under our conditions, MitoQ did not disrupt 
mitochondrial function and the decyl-TPP control compound was not protective. 
HG and hyperlipidaemia are related to mitochondrial ROS production in 
pancreatic β cells during T2D [7,31]. In fact, β cells are particularly susceptible to 
damage by ROS because of their reduced expression of antioxidant enzymes [33]. In 
 12 
relation to this, the results of the present study show that treatment with MitoQ reduces 
mitochondrial O2 consumption under HG conditions, as well as total and mitochondrial 
ROS, and enhances GSH levels, thus exhibiting an antioxidant effect. These results are 
in line with those of previous studies showing that MitoQ reduces ROS and modulates 
antioxidant activities such as glutathione peroxidase (GPX1) under oxidative stress 
conditions in propionic acidemia patient-derived fibroblasts [34] and in leukocytes from 
T2D patients [30]. Moreover, it is important to highlight that mitochondria-targeted 
antioxidants have also been demonstrated to maintain mitochondrial morphology, to 
restore intracellular ATP levels and to increase β cell survival under glucotoxic and 
glucolipotoxic conditions [31].  
It is well known that ER stress and oxidative stress are related [27,35], which in 
turn links ER stress to mitochondrial ROS. In this sense, several studies have focused 
their research on the contribution of ER stress to the development of insulin resistance 
and T2D [36, 37]. In addition, ER stress has been implicated in apoptosis of pancreatic 
β cells in a diabetic mouse model [38], and of leukocytes in T2D patients [27, 39]. 
Furthermore, Sage et al. [40] showed GRP78, sXBP1 and CHOP levels to be positively 
correlated with glucose levels in leukocytes from patients with metabolic syndrome. In 
accordance with these data, our present findings demonstrate that HG enhances levels of 
ER stress markers such as GRP78, P-eif2α, and intracellular calcium levels. 
Interestingly, MitoQ treatment reverses these effects, suggesting that this molecule 
ameliorates the mitochondrial disruption that leads on to ER stress.  
It is well known that oxidative stress leads to pro-inflammatory responses. 
Specifically, it has been reported that the increase of ROS production may activate the 
pro-inflammatory nuclear factor NFκB, thus contributing to insulin resistance [41,42]. 
In this sense, we have previously reported a significant increase in NFκB expression in 
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leukocytes of T2D patients [30]. For this reason, we decided to explore whether the 
antioxidant MitoQ has an effect on p65-NFκB protein expression in pancreatic β cells 
under HG. Our results show an increase in the protein NFκB-p65 under HG, which was 
reverted in the presence of MitoQ, thus identifying this molecule as a mitochondrial 
antioxidant capable of modulating not only oxidative stress and ER stress, but also 
inflammatory response. Furthermore, previous studies have demonstrated that glucose 
intolerance in obese mice is attenuated after inhibition of the IKKβ/NFκB pathway [43], 
which suggests this signaling pathway is a central player in the development of T2D. 
For this reason, we foresee MitoQ treatment as an option for the prevention and/or 
treatment of insulin resistance and, hence, T2D. 
Overall, our findings provide a better understanding of the pathophysiological 
mechanisms occurring in pancreatic β cells under HG. Importantly, our data show that 
treatment with MitoQ modulates mitochondrial function, ER stress and the NFκB 
signalling pathway, suggesting that this compound exerts beneficial effects that can be 
used to treat insulin resistance-related diseases such as T2D and/or obesity. 
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Figure 1. Effects of MitoQ (30 min, 0.5 µM) on mitochondrial function in 
pancreatic β cells under normoglycaemia and hyperglycaemia. (A) Oxygen 
consumption in a closed respiration chamber measured as nmol O2/min/10
6 cells. (B) 
Representative traces showing the rate of O2 consumption in a closed respiration 
chamber. (C) Mitochondrial membrane potential measured as TMRM fluorescence by 
fluorometry. (C) Mitochondrial ROS production measured as MitoSOX fluorescence by 
fluorometry. *p<0.05 with regard to control in normoglycaemia. ##p<0.01 when 
comparing groups treated and not treated with MitoQ in the hyperglycaemic condition 






Figure 2. Effects of MitoQ (30 min, 0.5 µM) on oxidative stress parameters in 
pancreatic β cells under normoglycaemia and hyperglycaemia. (A) ROS production 
measured as DCFH-DA fluorescence by fluorometry. (B) GSH levels measured as 
CMFDA fluorescence by fluorometry. *p<0.05 with regard to control in 
normoglycaemia. #p<0.05 comparing groups treated and not treated with MitoQ in the 















Figure 3. Evaluation of endoplasmic reticulum stress markers in pancreatic β cells 
under normoglycaemia and hyperglycaemia in the presence and absence of MitoQ 
(30 min, 0.5µM). (A) Protein levels of GRP78 and representative WB images. (B) 
Protein levels of P-eif2α and representative WB images. (C) Levels of intracellular 
calcium measured as Fluo-4 AM fluorescence by fluorometry. *p<0.05 and **p<0.01 
with regard to control in normoglycaemia. #p<0.05, ##p<0.01 when comparing groups 
treated and not treated with MitoQ in the hyperglycaemia condition (data represented as 







Figure 4. Evaluation of NFκB-p65 protein expression in pancreatic β cells under 
normoglycaemia and hyperglycaemia in the presence and absence of MitoQ (30 
min, 0.5 µM). Protein levels of NFκB-p65 and representative WB images. **p<0.01 
with regard to control in normoglycaemia. ##p<0.01 comparing groups treated and not 
treated with MitoQ in the hyperglycaemia condition (data represented as mean ± S.E.M, 
n=6). 
 
